Hyperion DeFi’s (HYPD) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Hyperion DeFi (NASDAQ:HYPD) in a research note published on Tuesday,Benzinga reports. They currently have a $7.30 target price on the stock.

A number of other equities analysts also recently issued reports on HYPD. Zacks Research upgraded Hyperion DeFi from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings upgraded Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Finally, Cantor Fitzgerald upped their price objective on Hyperion DeFi from $4.00 to $6.60 and gave the company an “overweight” rating in a research report on Wednesday, July 1st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.20.

Hyperion DeFi Trading Up 5.2%

Shares of HYPD stock opened at $2.83 on Tuesday. Hyperion DeFi has a 12-month low of $2.34 and a 12-month high of $15.00. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 0.12. The firm’s 50 day moving average is $2.91 and its 200 day moving average is $3.36. The stock has a market capitalization of $42.90 million, a P/E ratio of -0.43 and a beta of 2.53.

Hyperion DeFi (NASDAQ:HYPD) last posted its earnings results on Thursday, August 13th. The company reported $0.92 EPS for the quarter. The business had revenue of $0.36 million during the quarter. Hyperion DeFi had a net margin of 416.56% and a negative return on equity of 13.93%. Research analysts expect that Hyperion DeFi will post 1.69 earnings per share for the current year.

Insider Transactions at Hyperion DeFi

In other Hyperion DeFi news, insider Hyunsu Jung bought 7,000 shares of Hyperion DeFi stock in a transaction on Monday, June 1st. The stock was acquired at an average cost of $3.70 per share, with a total value of $25,900.00. Following the completion of the acquisition, the insider owned 1,384,676 shares in the company, valued at approximately $5,123,301.20. This represents a 0.51% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HYPD. Renaissance Technologies LLC bought a new stake in shares of Hyperion DeFi during the 4th quarter valued at $663,000. Jane Street Group LLC bought a new position in shares of Hyperion DeFi in the fourth quarter worth about $493,000. Focus Partners Advisor Solutions LLC purchased a new position in shares of Hyperion DeFi during the 4th quarter valued at about $221,000. Geode Capital Management LLC purchased a new position in shares of Hyperion DeFi during the 4th quarter valued at about $214,000. Finally, Investment House LLC bought a new position in shares of Hyperion DeFi during the 4th quarter valued at approximately $166,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.